TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04495751
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four pills twice daily.
Study: NCT05210374
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To be taken orally (PO) daily in the AM, rounded for pill size (max 480mg/day).~To be administered day 1-7 of lead-in week and day 1-28 cycles~Cycle length: 28 days,~maximum 12 cycles Level -1 (150mg/m\^2/day) Level~0 (225mg/m\^2/day) Level 1 (300mg/m\^2/day), max~480mg/day
Study: NCT05210374
Drug: Liposomal Doxorubicin (Doxil)
Normalized name: doxorubicin hydrochloride liposome Injection [Doxil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be given IV, 30mg/m2/dose~To be administered day 1 of cycles~Cycle length: 28 days, maximum 12 cycles
Study: NCT04889287
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single doses on Day 1, Day 8, and Day 13
Study: NCT04475835
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin is dosed at 100 U/kg. ACT is monitored 5 min after the first administration, and if the ACT \<225 s (Hemotec method), an intravenous injection of heparin should be administered by need.
Study: NCT06010537
Drug: polysaccharide superparamagnetic iron oxide injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide superparamagnetic iron oxide injection is a magnetic resonance contrast agent.
Study: NCT06007066
Drug: HSK16149 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given 40mg or 60mg of HSK16149 orally.
Study: NCT06007066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given HSK16149 placebo orally.
Study: NCT06391710
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous
Study: NCT04571151
Drug: LEXETTE 0.05% Topical Foam
Normalized name: LEXETTE 0.05% Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halobetasol Propionate Topical Foam (Lexette Foam) would be applied over the affected area twice daily for 2 weeks.
Study: NCT04571151
Drug: Sorilux 0.005 % Topical Foam
Normalized name: Sorilux 0.005 % Topical Foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol Foam (Sorilux Foam) would be applied over the affected area twice daily for 2 weeks 5 minutes after the Lexette application. SORILUX Foam contains calcipotriene 50 mcg/g.
Study: NCT06086392
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the supraclavicular brachial plexus block
Study: NCT04614246
Drug: BAY1817080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral administration
Study: NCT04614246
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral administration
Study: NCT06084897
Drug: TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice.
Approvals — FDA: no, EMA: no, PMDA: no
Description: A maximum of six cycles was recommended for chemotherapy.~* Fluoropyrimidine (fluorouracil or capecitabine) with carboplatin or cisplatin;~* Paclitaxel (or Albumin-bound paclitaxel) with carboplatin or cisplatin.
Study: NCT04941118
Drug: Injection of dextrose, local anesthetic and saline to the myofascial trigger point
Approvals — FDA: no, EMA: no, PMDA: no
Description: An injection of 5 ml of 5% dextrose prolotherapy using 2.5 ml 10% dextrose, 1 ml 2% local anesthetic (lidocaine), 1.5 ml 0.9% saline will be administered to the active group from at least 10 trigger points.
Study: NCT04941118
Drug: Local anesthetic and saline injection to the myofascial trigger point
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total of 5 ml of solution created by using 4 ml of 0.9% saline and 1 ml of 2% local anesthetic (lidocaine) will be administered to the control group, with at least 10 trigger points.
Study: NCT06585462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by SC or IV injection.
Study: NCT06115967
Drug: AZD6912
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD6912 will be administered as a single sub-cutaneous dose.
Study: NCT05191017
Drug: NUV-422
Approvals — FDA: no, EMA: no, PMDA: no
Description: NUV-422 is an investigational drug for oral dosing.
Study: NCT06115967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a single sub-cutaneous dose.
Study: NCT04899388
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intavenous
Study: NCT04540354
Drug: Optimal Medical Therapy (OMT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated according to Optimal Medical Therapy defined by the 2016 ESC guidelines for the management of acute and chronic heart failure.
Study: NCT06186934
Drug: the standard-dose group (4 g/day)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with chronic kidney disease undergoing hemodialysis and controlling hyperphosphatemia
Study: NCT06408948
Drug: [14C]SHR7280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive single dose of orally \[14C\]SHR7280 on Day 1.
Study: NCT05699486
Drug: PDNO
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
Study: NCT05471492
Drug: Investigational Product
Normalized name: INVESTIGATIONAL AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06480605 150 mg
Study: NCT05471492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05632328
Drug: AGEN1423
Approvals — FDA: no, EMA: no, PMDA: no
Description: via IV, dosage per protocol, once every 2 weeks for up to 8 weeks
Study: NCT06606106
Drug: LY3537031
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06606106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06138236
Drug: Collagen hydrolyzed peptides
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: infiltration near the heal spur of 2ml of Arthrys
Study: NCT06388759
Drug: TQ05105 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQ05105 Tablets is a Janus kinase 1 (JAK1) and Janus kinase 2 （JAK2） Inhibitor
Study: NCT06165250
Drug: BR1018A-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06165250
Drug: BR1018C
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT05006768
Drug: Barcimiant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 4 mg Barcitinib
Study: NCT05202262
Drug: BFF MDI 160/9.6 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/ Formoterol Fumarate (BFF) metered-dose inhaler (MDI), 160/9.6 μg
Study: NCT05202262
Drug: Open-label Symbicort TBH 320/9 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label Symbicort Turbuhaler 320/9 μg
Study: NCT05488860
Drug: 5-ALA (a photosensitizer for photodynamic therapy).
Approvals — FDA: no, EMA: no, PMDA: no
Description: For other diseases, the drug is 5-ALA (a photosensitizer for photodynamic therapy).
Study: NCT06586606
Drug: MK-1708
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT04780269
Drug: Induction of labor with PGE2
Normalized name: Antivirals for treatment of HCV infections
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 (1mg) will be inserted into the posterior vaginal fornix. Women will be assigned one hour of bed rest while continuously monitored by cardiotocography.
Study: NCT06277752
Drug: dose-5 group
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI128 300mg po. QD(Quaque Die)
Study: NCT06277752
Drug: dose-1 group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI128 25mg po. QD(Quaque Die)
Study: NCT06277752
Drug: dose-2 group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI128 50mg po. QD(Quaque Die)
Study: NCT06277752
Drug: dose-4 group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI128 200mg po. QD(Quaque Die)
Study: NCT06277752
Drug: dose-3 group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IBI128 100mg po. QD(Quaque Die)
Study: NCT05313997
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: at first diclofenac sodium was prescribed to patients with chronic upper back pain.~If the patient's pain persisted, she/he was included in the physical therapy (hotpack 20 minutes, ultrason 5 minutes, Transcutaneous electrical nerve stimulation 20 minutes) program.
Study: NCT04271332
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manufactured to match Arbaclofen in size, shape, color and taste
Study: NCT00592618
Drug: Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06632470
Drug: Secretome injection
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will receive 3 ml of secretome intramuscular injection every two weeks for four months
Study: NCT05136625
Drug: Standard Preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Troncular scalp blockade. Local site infiltration
Study: NCT06601452
Drug: a compound prescription of Chinese medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The enrolled patients were treated with 3 cycles of sequential treatment with Nourishing Yin and Replenishing Yang formula before entering the cycle (Tuning Weekly Nourishing Yin Granules + Tuning Weekly Replenishing Yang Granules), and the egg retrieval cycle used an antagonist regimen to obtain the eggs.
Study: NCT06126991
Drug: Midazolam and Fentanyl
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 50mg + fentanyl 300ug micro pump push will be used with a starting dose of 5ml/hour, adjusted according to the patient's level of sedation. The patient's RASS score will be maintained between -1-0 and the drug will be suspended with a blood pressure below 90/60mmHg.
Study: NCT04702009
Drug: Anti-PD-1/PD-L1 Monoclonal Antibody，Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-PD-1/PD-L1 monoclonal antibody (approved anti-PD-1/PD-L1 monoclonal antibody)；albumin paclitaxel/docetaxel + carboplatin (albumin paclitaxel 130mg/m2, d1 d8, Docetaxel 75mg/m2, carboplatin AUC=5, d1, every 21 days, 4 cycles of chemotherapy; immunotherapy no more than 2 years)
Study: NCT01222650
Drug: KSO-0400
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01222650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06222944
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450: 1200 mg, IV, D1, Q3W
Study: NCT04221880
Drug: Saline Solution intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same volume saline solution bolus and infusion as Group Lidocaine
Study: NCT05325775
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05322213
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-Week, once daily, flexible dose, inhaled placebo
Study: NCT06217120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily
Study: NCT04674566
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously (IV) single dose
Study: NCT04023708
Drug: CYD-TDV Dengue Vaccine
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution Route of administration: Intramuscular
Study: NCT06095388
Drug: JR-441
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT04739709
Drug: APP13007, 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: APP13007 eye drop, 0.05%
Study: NCT04739709
Drug: Matching Vehicle Placebo for APP13007, 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle placebo eye drop
Study: NCT04994236
Drug: Hepatic artery infusion chemotherapy with FOLFOX regimens (oxaliplatin, fluorouracil, and leucovorin)
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: The FOLFOX regiments were given via hepatic artery catheterization, including oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2, followed by fluorouracil infusion 2400 mg/m2 for 46 hours. If no severe adverse events occurred, the treatment will be repeated every 3 weeks.
Study: NCT06142552
Drug: FRSW117
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a week, 50 weeks and as needed
Study: NCT05152940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with matching placebo to ertugliflozin administered orally once daily for a period of one month
Study: NCT04821583
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone is orally administered.
Study: NCT04821583
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is orally administered.
Study: NCT04692688
Drug: APX3330
Approvals — FDA: no, EMA: no, PMDA: no
Description: APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.
Study: NCT04692688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.
Study: NCT05084404
Drug: Experimental: 4 mg/day of WY-8678 (guanabenz acetate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with nonalcoholic fatty liver disease are administered 4 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
Study: NCT05084404
Drug: Experimental: 8 mg/day of WY-8678 (guanabenz acetate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with nonalcoholic fatty liver disease are administered 8 mg/day of WY-8678 (guanabenz acetate) twice daily for 16 weeks
Study: NCT05202145
Drug: ALXN2050
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet.
Study: NCT04914221
Drug: JLP-2002
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of JLP-2002
Study: NCT04914221
Drug: Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of comparator
Study: NCT06133166
Drug: EG017 ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
Study: NCT06133166
Drug: EG017 ointment placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply once a night on the skin side of both eyelids at bedtime, approximately 100 mg/eye per dose, for 8 weeks
Study: NCT04709835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.
Study: NCT05861271
Drug: Capecitabine，Pyrotinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib and Capecitabine for half a year
Study: NCT05389696
Drug: Single subcutaneous administration and Blood collection
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous administration and Blood collection
Study: NCT05389696
Drug: Single subcutaneous administration and then IV injection.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous administration and then single intravenous administration after 2 weeks. In addition Blood collection is conducted as scheduled.
Study: NCT05540327
Drug: M5049 medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive film-coated tablets of M5049 at a medium dose orally, BID for up to 48 weeks.
Study: NCT05540327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive M5049 matching placebo orally, BID for up to 48 weeks.
Study: NCT06145074
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT06216340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and diet-exercise therapy
Study: NCT05702268
Drug: ICP-332
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 40 mg
Study: NCT05702268
Drug: ICP-332 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, in appearance, size, color, dosage form, packaging, instructions, labels and other aspects of the corresponding specifications of ICP-332.
Study: NCT06169085
Drug: Leritrelvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04711902
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection
Study: NCT05951686
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion will be used with a dose of 0.05-2 mcg/ kg/ min under the screening with Patient State Index (PSI) between a score of 25-50 in both groups.
Study: NCT06430060
Drug: zinc containing toothpaste
Normalized name: monofluorophosphate / potassium nitrate / zinc citrate Toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste
Study: NCT04740970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo injection will be administered subcutaneously.
Study: NCT06403501
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream manufactured to mimic look and feel of Clascoterone Cream 1% but without the active ingredient.
Study: NCT05161936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by SC injection.
Study: NCT05842707
Drug: dualCAR-NK19/70 cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT05721027
Drug: Ibuprofen 400 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400 mg PO every 8 hours as needed for 7 days
Study: NCT04837170
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving conventional therapy without S (+)-Ketamine hydrochloride injection. There is no restrictions in drugs, doses and incompatibility, the researchers can choose appropriate medication regimens based on clinical practice, but other NMDA receptor antagonists are not be allowed to use, such as dextromethorphan and amantadine.
Study: NCT05998447
Drug: mFOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX given by intravenous (IV) once every 2 weeks for only cohort 3
Study: NCT04801693
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04817982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be added perineurally to an ulnar nerve block with bupivacaine.
Study: NCT05442632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients received Placebo 5mg orally d1-14 days, surgery will be conducted at d6-14 day
Study: NCT00009555
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04915300
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo p.o. (tablets) BID for 24 weeks treatment period.
Study: NCT05352113
Drug: SSRIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs antidepressants will be used and the oral dose will be determined by the clinical specialist. Once-daily for 6 weeks.
Study: NCT05352113
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo mimicking SSRIs antidepressants. Once-daily for 6 weeks.
Study: NCT04723069
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: metronidazole tablets + doxycycline hyclate tablets, are consecutively taken for 14 days, while Fuke Qianjin capsule simulation is consecutively taken for 28 days.
Study: NCT04723069
Drug: Test Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: metronidazole tablets + doxycycline hyclate tablets simulant are consecutively taken for 14 days, while Fuke Qianjin capsule is consecutively taken for 28 days.
Study: NCT05876312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT05486468
Drug: Yutiq 0.18 MG Drug Implant
Normalized name: Yutiq 0.18 MG Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for intravitreal injection
Study: NCT04093076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered ID on Day 0 and Week 4.
Study: NCT06466265
Drug: DNP002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-CEACAM6 monoclonal antibody
Study: NCT05593458
Drug: SOX neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of SOX neoadjuvant chemotherapy every 21 days.
Study: NCT05593458
Drug: SOX adjuvant, Sequential S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of SOX adjuvant chemotherapy every 21 days after surgery in both groups.~Sequential S-1 chemotherapy every 21 days till 1 year postoperation.
Study: NCT05207358
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will receive Cyclophosphamide intravenously starting day 1, 6 pulses at a fixed dose of 500 mg given at 2 weeks. After 3 months, Azathioprine (2 mg / kg / day) is initiated 2 weeks after the last administration of Cyclophosphamide and maintained for the next 21 months.
Study: NCT05207358
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 daily pulses of 750 mg of intravenous Methylprednisolone, followed by oral corticosteroid therapy starting with a dose of 0.5 mg / kg / day for 4 weeks, then decreased by 2.5 mg of Prednisolone / day each 2 weeks. A low dose of glucocorticoid (5-7.5 mg / day) is maintained until 24 months after enrollment.